Dell Joins Forces with Nvidia to Launch Faster AI Servers
On May 19, Dell Technologies (NYSE:DELL) announced plans to join hands with NVIDIA Corporation (NASDAQ:NVDA) to launch new and better AI servers powered by the latter's Blackwell Ultra chips. The collaboration aims to capitalize on the booming demand for AI systems.
According to Dell Technologies (NYSE:DELL), these severs hold the potential to train AI models as much as four times faster than the previous models.
A technician standing in front of a wall of servers, managing the public wireless network.
The servers are available in two variants: liquid-cooled and air-cooled, and can support up to 192 Nvidia Blackwell Ultra chips. However, they can be customized to contain up to 256 chips.
Reuters reported that Arthur Lewis, President of Dell's Infrastructure Solutions Group, expects the pricing of these products to be "competitive," saying that "there's a lot of interest on what's next".
While we acknowledge the potential of DELL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DELL and that has 100x upside potential, check out our report about the .
READ NEXT: and .
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week
The company's CFO resigned from his position. One law firm wasn't shy about reminding investors of the departure. 10 stocks we like better than Iovance Biotherapeutics › There's nothing like a top-level management departure to get investors worried about a publicly traded company. Investors in biotech stock Iovance Therapeutics (NASDAQ: IOVA) were served a strong reminder of the company's latest executive departure earlier in the week. With that headwind blowing in its face, Iovance's shares lost almost 15% of their value during the week, according to data compiled by S&P Global Market Intelligence. Hagens Berman Sobol Shapiro, one of the numerous law firms currently investigating Iovance's activities, was behind the reminder. It pointed out that CFO Jean-Marc Bellemin stepped down from his post earlier in June. His resignation is effective this coming July 10. The law firm hinted that the cancer-focused biotech company's legal headaches were at least partially responsible for this. It wrote in a press release that "Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the specter of a class action securities lawsuit." Iovance originally disclosed the CFO's resignation on Friday, June 13 in a tersely worded regulatory filing with the Securities and Exchange Commission (SEC). It said only that Bellemin made the move "to pursue other opportunities." It did not elaborate on this. Besides its legal headaches, Iovance is struggling to produce impressive fundamentals. Although it delivered decent top-line growth -- thanks to Amtagvi, a melanoma drug -- it made quite a drastic cut to its product-revenue guidance for the entirety of this year. I don't think Iovance is in a good place just now. However, Amtagvi still has much potential, and the biotech is a player to watch in the cancer space. It might just be worthy of a buy for investors with a large appetite for risk. Before you buy stock in Iovance Biotherapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Iovance Biotherapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $704,676!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $950,198!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy. Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week was originally published by The Motley Fool Sign in to access your portfolio
Business Insider
2 hours ago
- Business Insider
BBAI vs. CRWV vs. APP: Which Growth Stock Is the Best Pick, According to Wall Street Analysts?
Macro uncertainties, geopolitical tensions, and news on the tariff front have kept the stock market volatile. Despite ongoing uncertainties, analysts remain optimistic about several growth stocks and their potential to generate attractive returns over the long term. Using TipRanks' Stock Comparison Tool, we placed BigBear. ai Holdings (BBAI), CoreWeave (CRWV), and AppLovin (APP) against each other to find the best growth stock, according to Wall Street analysts. Confident Investing Starts Here: Holdings (NYSE:BBAI) Stock Holdings stock has risen more than 31% so far in 2025 and 292% over the past year, as investors are optimistic about the prospects of the data analytics company. BBAI offers artificial intelligence (AI)-powered decision intelligence solutions, mainly focused on national security, defense, and critical infrastructure. The company ended Q1 2025 with a backlog of $385 million, reflecting 30% year-over-year growth. However, there have been concerns about low revenue growth rate and high levels of debt. Looking ahead, the company is pursuing further growth through international expansion and strategic partnerships, while continuing to secure attractive government business. What Is the Price Target for BBAI Stock? Last month, Northland Securities analyst Michael Latimore reaffirmed a Hold rating on BBAI stock but lowered his price target to $3.50 from $4 after the company missed Q1 estimates due to further delays in government contracts. On the positive side, the 4-star analyst noted the solid growth in backlog and management's statement that their strategy is 'beginning to resonate.' On TipRanks, Holdings stock is assigned a Moderate Buy consensus rating, backed by two Buys and two Holds. The average BBAI stock price target of $4.83 indicates a possible downside of 17.3% from current levels. CoreWeave (NASDAQ:CRWV) Stock CoreWeave, a cloud provider specializing in AI infrastructure, is seeing robust adoption for its products. The company, which provides customers access to Nvidia's (NVDA) GPUs (graphics processing units), went public in March. CRWV stock has risen about 300% to $159.99, compared to its IPO (initial public offering) price of $40. Remarkably, CoreWeave delivered a 420% jump in its Q1 2025 revenue to $981.6 million. Moreover, the company ended the first quarter of 2025 with a robust backlog of $25.9 billion. Meanwhile, CoreWeave has entered into lucrative deals, including an expanded agreement of up to $4 billion with ChatGPT-maker OpenAI and a collaboration to power the recently announced cloud deal between Alphabet's Google (GOOGL) and OpenAI. Is CRWV a Good Stock to Buy? Recently, Bank of America analyst Bradley Sills downgraded CoreWeave stock to Hold from Buy, citing valuation concerns following the strong rally after the company's Q1 results. Also, the 4-star analyst expects $21 billion of negative free cash flow through 2027, due to elevated capital expenditure ($46.1 billion through 2027). However, Sills raised the price target for CRWV stock to $185 from $76, noting several positives, including the OpenAI deal and strong revenue momentum. Overall, Wall Street has a Moderate Buy consensus rating on CoreWeave stock based on six Buys, 11 Holds, and one Sell recommendation. At $78.53, the average CRWV stock price target indicates a substantial downside risk of about 51%. AppLovin (NASDAQ:APP) Stock Adtech company AppLovin has witnessed a 301% jump in its stock price over the past year. The company provides end-to-end software and AI solutions for businesses to reach, monetize, and grow their global audiences. Notably, AppLovin's strong growth rates have impressed investors. In Q1 2025, AppLovin's revenue grew 40% and earnings per share (EPS) surged by 149%. Investors have also welcomed the company's decision to sell its mobile gaming business to Tripledot Studios. The move is expected to enable AppLovin to focus more on its AI-powered ad business. However, APP stock has declined more than 12% over the past month due to the disappointment related to its non-inclusion in the S&P 500 Index (SPX) and accusations by short-seller Casper Research. Nonetheless, most analysts remain bullish on AppLovin due to its strong fundamentals and demand for the AXON ad platform. Is APP a Good Stock to Buy Recently, Piper Sandler analyst James Callahan increased the price target for AppLovin stock to $470 from $455 and reaffirmed a Buy rating. While Piper Sandler's checks suggest some weakness in AppLovin's supply-side trends, it remains a buyer of APP stock, with the tech company growing well above its digital ad peers and expanding into new verticals. With 16 Buys and three Holds, AppLovin stock scores a Strong Buy consensus rating. The average APP stock price target of $504.18 indicates 51% upside potential from current levels. Conclusion Wall Street is sidelined on stock, cautiously optimistic on CoreWeave, and highly bullish on AppLovin stock. Analysts see higher upside potential in APP stock than in the other two growth stocks. Wall Street's bullish stance on AppLovin stock is backed by solid fundamentals and strong momentum in its AI-powered ad business. According to TipRanks' Smart Score System, APP stock scores a 'Perfect 10,' indicating that it has the ability to outperform the broader market over the long run.
Yahoo
3 hours ago
- Yahoo
Intrusion Inc. (INTZ) Stock Falls Amid Market Uptick: What Investors Need to Know
Intrusion Inc. (INTZ) closed the most recent trading day at $2.23, moving -5.51% from the previous trading session. This move lagged the S&P 500's daily gain of 0.52%. On the other hand, the Dow registered a gain of 1%, and the technology-centric Nasdaq increased by 0.52%. Heading into today, shares of the company had gained 74.82% over the past month, outpacing the Computer and Technology sector's gain of 9.55% and the S&P 500's gain of 5.95%. The investment community will be paying close attention to the earnings performance of Intrusion Inc. in its upcoming release. The company's earnings per share (EPS) are projected to be -$0.09, reflecting a 83.02% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $1.8 million, up 23.29% from the prior-year quarter. For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.36 per share and a revenue of $7.65 million, signifying shifts of +77.91% and +32.56%, respectively, from the last year. It's also important for investors to be aware of any recent modifications to analyst estimates for Intrusion Inc. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Intrusion Inc. is currently a Zacks Rank #3 (Hold). The Computer - Networking industry is part of the Computer and Technology sector. At present, this industry carries a Zacks Industry Rank of 181, placing it within the bottom 27% of over 250 industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow INTZ in the coming trading sessions, be sure to utilize Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intrusion Inc. (INTZ) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
